FOXO4-DRI 10mg

FOXO4-DRI is studied in the laboratory setting to explore the following: 

• In vitro assays: Measuring solubility, degradation rates, and molecular interactions in cell-free or cell-based models.
• Spectroscopic and chromatographic analysis: Learning about purity, sequence confirmation, and physicochemical stability.
• Computational modeling: Predicting molecular folding, binding affinity, and secondary structure formation.
• Peptide engineering comparisons: Assessing how reversed sequences and D-amino acid substitutions affect molecular resilience.
• Reconstitution and formulation studies: Investigating the effects on solvent compatibility and solution behavior under laboratory conditions.
   

• Cellular signaling research: Investigating how modified peptides influence intracellular communication and regulatory pathways.
• Molecular biology: Exploring peptide-protein recognition mechanisms and conformational dynamics.
• Chemical biology: Experimental studies examining structure-activity relationships and how stereochemistry affects molecular interactions.
• Ex vivo systems: Studying peptide distribution and stability in isolated tissue environments.
• Analytical chemistry: Developing or validating laboratory techniques for purity, sequence verification, and degradation profiling.
• Peptide design and synthesis: Lab research exploring next-generation analog development through data on molecular folding, solubility, and binding behavior.

FOXO4-DRI is a synthetic peptide supplied as a lyophilized powder for controlled laboratory research. It is formulated for use in studies examining peptide stability, solubility, and molecular interactions under in vitro or ex vivo conditions. Each vial contains research-grade material designed to support reproducible experimentation and accurate analytical results. This product is intended exclusively for research use.

1. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes

2. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation

3. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice

4. FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells

5. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

All products on this site are for research, laboratory, or analytical use only and are not for human consumption. These products and the statements on this website have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure, or prevent any disease. PowerPeptides is not a compounding or outsourcing pharmacy under 503A/503B of the Federal Food, Drug, and Cosmetic Act. By purchasing or using these products, you agree to use them solely for lawful research purposes and accept full responsibility for their use.